Gilead Discloses Over $2.1B in Strategic Equity Holdings, Including Pre-Acquisition Arcellx Stake

summarizeSummary

Gilead Sciences, through its investment arm, reported total equity holdings exceeding $2.1 billion as of Q1 2026, providing insight into its strategic investments and confirming its significant stake in Arcellx prior to the recent acquisition.

check_boxKey Events

• Discloses Over $2.1 Billion in Equity Holdings

  Gilead Sciences, through its investment management arm, reported total equity holdings valued at $2,117,784,504 as of March 31, 2026.

• Confirms Significant Arcellx Stake

  The filing shows a holding of Arcellx Inc. shares valued at $771,682,600, representing Gilead's substantial stake prior to its $7.1 billion acquisition of Arcellx completed on April 28, 2026.

• Details Strategic Biotech Investments

  The report outlines significant equity positions in key partners like Arcus Biosciences ($678.7M) and Galapagos NV ($501.2M), alongside smaller stakes in Assembly Biosciences, Kyverna Therapeutics, and Xilio Therapeutics.

auto_awesomeAnalysis

This 13F-HR filing from Gilead Sciences itself, rather than a third-party institutional investor, offers a detailed look into the company's strategic equity investments in other biotechnology firms. The report confirms Gilead held a significant stake in Arcellx Inc. valued at over $771 million as of March 31, 2026, which precedes the completion of its $7.1 billion acquisition of Arcellx on April 28, 2026. This filing provides transparency into Gilead's portfolio of collaborations and strategic partnerships, including long-standing investments in Arcus Biosciences and Galapagos NV, which are key to its R&D pipeline and future growth.